In a bid to overturn the largest award yet to come out of the Risperdal mass tort program in Philadelphia, Janssen Pharmaceuticals has outlined challenges—beginning with questioning the sufficiency of evidence—to numerous rulings in the case that resulted in a $70 million verdict last summer.
Janssen filed Wednesday a list of what it contends were errors that the trial court made during the litigation in A.Y. v. Janssen Pharmaceuticals. The filing contested the sufficiency of the evidence on numerous issues, argued that the court improperly limited its ability to tell the jury about the benefits of Risperdal, and the court should not have applied a $750,000 damages cap to the case.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
